Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 624 | -2,793 | -4,269 | -12,032 | -9,695 |
| Depreciation Amortization | 356 | 549 | 65 | 48 | 60 |
| Accounts receivable | -245 | N/A | N/A | N/A | N/A |
| Other Working Capital | 196 | -219 | -972 | -3 | 208 |
| Other Operating Activity | -2,901 | 1,414 | 732 | 1,757 | 1,677 |
| Operating Cash Flow | $-1,970 | $-1,050 | $-4,444 | $-10,230 | $-7,751 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | N/A | N/A | 1,006 |
| PPE Investments | -3 | N/A | -9 | -9 | -37 |
| Net Acquisitions | 519 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $517 | $N/A | $-9 | $-9 | $969 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 40 | 1,032 | 3,759 | N/A | N/A |
| Debt Repayment | -289 | -43 | N/A | N/A | N/A |
| Common Stock Issued | 2,164 | N/A | 150 | 7,859 | -15 |
| Financing Cash Flow | $1,914 | $989 | $3,909 | $7,859 | $-15 |
| Beginning Cash Position | 18 | 106 | 650 | 3,029 | 9,826 |
| End Cash Position | 479 | 45 | 106 | 650 | 3,029 |
| Net Cash Flow | $461 | $-61 | $-544 | $-2,379 | $-6,797 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,970 | -1,050 | -4,444 | -10,230 | -7,751 |
| Capital Expenditure | -3 | N/A | -9 | -9 | -37 |
| Free Cash Flow | -1,973 | -1,050 | -4,453 | -10,239 | -7,788 |